7/120
0.3 / 5 stars
All 120 Win/Lose results shown below
CLYM Roast Me summary
Climb Bio, Inc. (CLYM). Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Lose.
Trailing 1 year (4 quarters): 4 wins, 8 lossesLast fetched: 24 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
WinCLYM / S&P 90.36% / 15.20% |
LoseCLYM / S&P CLYM unavailable / 15.00% |
LoseCLYM / S&P CLYM unavailable / 50.40% |
| 2026-Q11/3 |
WinCLYM / S&P 71.25% / -4.33% |
LoseCLYM / S&P CLYM unavailable / 11.30% |
LoseCLYM / S&P CLYM unavailable / 27.70% |
| 2025-Q41/3 |
WinCLYM / S&P 99.00% / 2.65% |
LoseCLYM / S&P CLYM unavailable / 9.00% |
LoseCLYM / S&P CLYM unavailable / 13.40% |
| 2025-Q31/3 |
WinCLYM / S&P 62.10% / 8.12% |
LoseCLYM / S&P CLYM unavailable / 4.61% |
LoseCLYM / S&P CLYM unavailable / 13.45% |
| 2025-Q20/3 |
LoseCLYM / S&P 1.64% / 10.94% |
LoseCLYM / S&P CLYM unavailable / 4.83% |
LoseCLYM / S&P CLYM unavailable / 10.63% |
| 2025-Q10/3 |
LoseCLYM / S&P -32.22% / -4.27% |
LoseCLYM / S&P CLYM unavailable / 4.98% |
LoseCLYM / S&P CLYM unavailable / 10.57% |
| 2024-Q40/3 |
LoseCLYM / S&P -64.64% / 2.41% |
LoseCLYM / S&P CLYM unavailable / 5.25% |
LoseCLYM / S&P CLYM unavailable / 6.15% |
| 2024-Q30/3 |
LoseCLYM / S&P -28.41% / 5.89% |
LoseCLYM / S&P CLYM unavailable / 5.89% |
LoseCLYM / S&P CLYM unavailable / 6.11% |
| 2024-Q21/3 |
WinCLYM / S&P 159.49% / 4.28% |
LoseCLYM / S&P CLYM unavailable / 5.38% |
LoseCLYM / S&P CLYM unavailable / 5.12% |
| 2024-Q10/3 |
LoseCLYM / S&P 1.48% / 10.56% |
LoseCLYM / S&P CLYM unavailable / 5.71% |
LoseCLYM / S&P CLYM unavailable / 5.59% |
| 2023-Q40/3 |
LoseCLYM / S&P 2.66% / 11.69% |
LoseCLYM / S&P CLYM unavailable / 6.81% |
LoseCLYM / S&P CLYM unavailable / 7.78% |
| 2023-Q30/3 |
LoseCLYM / S&P -6.07% / -3.27% |
LoseCLYM / S&P CLYM unavailable / 7.52% |
LoseCLYM / S&P -14800.00% / -5.03% |
| 2023-Q20/3 |
LoseCLYM / S&P -3.45% / 8.74% |
LoseCLYM / S&P CLYM unavailable / 9.50% |
LoseCLYM / S&P CLYM unavailable / -8.57% |
| 2023-Q10/3 |
LoseCLYM / S&P -20.98% / 7.50% |
LoseCLYM / S&P CLYM unavailable / 10.77% |
LoseCLYM / S&P CLYM unavailable / -15.69% |
| 2022-Q41/3 |
WinCLYM / S&P 13.62% / 7.56% |
LoseCLYM / S&P CLYM unavailable / 11.88% |
LoseCLYM / S&P CLYM unavailable / -17.99% |
| 2022-Q31/3 |
WinCLYM / S&P 6.95% / -4.88% |
LoseCLYM / S&P CLYM unavailable / 13.47% |
LoseCLYM / S&P CLYM unavailable / -1.41% |
| 2022-Q20/3 |
LoseCLYM / S&P -64.00% / -16.10% |
LoseCLYM / S&P CLYM unavailable / 13.71% |
LoseCLYM / S&P CLYM unavailable / 11.04% |
| 2022-Q10/3 |
LoseCLYM / S&P -19.79% / -4.60% |
LoseCLYM / S&P CLYM unavailable / 15.97% |
LoseCLYM / S&P CLYM unavailable / 42.23% |
| 2021-Q40/3 |
LoseCLYM / S&P -41.82% / 11.03% |
LoseCLYM / S&P CLYM unavailable / 15.00% |
LoseCLYM / S&P CLYM unavailable / 96.40% |
| 2021-Q30/3 |
LoseCLYM / S&P CLYM unavailable / 0.58% |
LoseCLYM / S&P CLYM unavailable / 10.77% |
LoseCLYM / S&P CLYM unavailable / 69.42% |
| 2021-Q20/3 |
LoseCLYM / S&P CLYM unavailable / 8.55% |
LoseCLYM / S&P CLYM unavailable / 6.58% |
LoseCLYM / S&P CLYM unavailable / 51.81% |
| 2021-Q10/3 |
LoseCLYM / S&P CLYM unavailable / 6.17% |
LoseCLYM / S&P CLYM unavailable / -1.06% |
LoseCLYM / S&P CLYM unavailable / 7.39% |
| 2020-Q40/3 |
LoseCLYM / S&P CLYM unavailable / 12.15% |
LoseCLYM / S&P CLYM unavailable / -3.72% |
LoseCLYM / S&P CLYM unavailable / -33.42% |
| 2020-Q30/3 |
LoseCLYM / S&P CLYM unavailable / 8.93% |
LoseCLYM / S&P CLYM unavailable / -2.04% |
LoseCLYM / S&P CLYM unavailable / -27.10% |
| 2020-Q20/3 |
LoseCLYM / S&P CLYM unavailable / 20.54% |
LoseCLYM / S&P CLYM unavailable / -0.46% |
LoseCLYM / S&P CLYM unavailable / -27.11% |
| 2020-Q10/3 |
LoseCLYM / S&P CLYM unavailable / -19.60% |
LoseCLYM / S&P CLYM unavailable / 3.47% |
LoseCLYM / S&P CLYM unavailable / -14.75% |
| 2019-Q40/3 |
LoseCLYM / S&P CLYM unavailable / 9.07% |
LoseCLYM / S&P CLYM unavailable / 5.36% |
LoseCLYM / S&P CLYM unavailable / 2.99% |
| 2019-Q30/3 |
LoseCLYM / S&P CLYM unavailable / 1.70% |
LoseCLYM / S&P CLYM unavailable / 5.02% |
LoseCLYM / S&P CLYM unavailable / 0.21% |
| 2019-Q20/3 |
LoseCLYM / S&P CLYM unavailable / 4.30% |
LoseCLYM / S&P CLYM unavailable / 6.64% |
LoseCLYM / S&P CLYM unavailable / 8.65% |
| 2019-Q10/3 |
LoseCLYM / S&P CLYM unavailable / 13.65% |
LoseCLYM / S&P CLYM unavailable / 8.12% |
LoseCLYM / S&P CLYM unavailable / 14.29% |
| 2018-Q40/3 |
LoseCLYM / S&P CLYM unavailable / -13.52% |
LoseCLYM / S&P CLYM unavailable / 9.05% |
LoseCLYM / S&P CLYM unavailable / 18.23% |
| 2018-Q30/3 |
LoseCLYM / S&P CLYM unavailable / 7.71% |
LoseCLYM / S&P CLYM unavailable / 10.21% |
LoseCLYM / S&P CLYM unavailable / 19.06% |
| 2018-Q20/3 |
LoseCLYM / S&P CLYM unavailable / 3.43% |
LoseCLYM / S&P CLYM unavailable / 9.03% |
LoseCLYM / S&P CLYM unavailable / 14.46% |
| 2018-Q10/3 |
LoseCLYM / S&P CLYM unavailable / -0.76% |
LoseCLYM / S&P CLYM unavailable / 7.68% |
LoseCLYM / S&P CLYM unavailable / 12.46% |
| 2017-Q40/3 |
LoseCLYM / S&P CLYM unavailable / 6.64% |
LoseCLYM / S&P CLYM unavailable / 7.03% |
LoseCLYM / S&P CLYM unavailable / 13.82% |
| 2017-Q30/3 |
LoseCLYM / S&P CLYM unavailable / 4.48% |
LoseCLYM / S&P CLYM unavailable / 5.68% |
LoseCLYM / S&P CLYM unavailable / 17.57% |
| 2017-Q20/3 |
LoseCLYM / S&P CLYM unavailable / 3.09% |
LoseCLYM / S&P CLYM unavailable / 4.83% |
LoseCLYM / S&P CLYM unavailable / 17.74% |
| 2017-Q10/3 |
LoseCLYM / S&P CLYM unavailable / 6.07% |
LoseCLYM / S&P CLYM unavailable / 3.67% |
LoseCLYM / S&P CLYM unavailable / 13.32% |
| 2016-Q40/3 |
LoseCLYM / S&P CLYM unavailable / 3.82% |
LoseCLYM / S&P CLYM unavailable / 2.09% |
LoseCLYM / S&P CLYM unavailable / 7.05% |
| 2016-Q30/3 |
LoseCLYM / S&P CLYM unavailable / 3.85% |
LoseCLYM / S&P CLYM unavailable / 0.20% |
LoseCLYM / S&P CLYM unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-28
| Metric | CLYM total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 552.50% | 20.78% |
| Annualized return | 552.50% | 20.78% |
5Y · 2021-09-01 to 2026-08-28
| Metric | CLYM total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -45.91% | 83.14% |
| Annualized return | -11.56% | 12.86% |
10Y · 2021-08-10 to 2026-08-28
| Metric | CLYM total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -8.49% | 319.30% |
| Annualized return | -0.88% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-24.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |